The purpose of this study is to demonstrate that virologically controlled HIV-infected individuals can successfully switch from a standard-of-care regimen dosed twice-daily or more frequently to a simpler once-daily (QD) regimen while maintaining virologic control, as evaluated by the proportion of subjects who continue to have plasma HIV-1 levels <50 copies/mL after switching to a QD regimen.

Inclusion Criteria:

• Documented HIV infection
• 18 years of age or older and weigh at least 40 kg
• Two plasma HIV RNA levels below the limit of quantification (one at least 90 days prior to the screening visit and one within 30 days of the patients baseline visit)
• Currently receiving a standard-of-care HAART regimen with at least one agent being dosed twice-daily or more frequently

Exclusion Criteria:

• Pregnancy, breastfeeding or plans to become pregnant during the study period
• Any prior documented virologic failure to one or more HAART regimens
• Active AIDS-defining opportunistic infection or disease
• Proven or suspected acute hepatitis within 30 days prior to study entry